Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Pro-Pharmaceuticals has appointed Theodore Zucconi, a member of the company's board of directors and former president, as its new CEO and president.
Subscribe to our email newsletter
Dr Zucconi replaces David Platt, who will become CEO and chief technology officer of Medi-Pharmaceuticals, a company that is 10% owned by Pro-Pharmaceuticals that is engaged in developing cardiovascular treatments. The company also announced that Anatole Klyosov has returned to Pro-Pharmaceuticals as chief scientist.
In addition, Gilbert Amelio, James Czirr, Rod Martin and Peter Traber were named to the company’s board of directors replacing directors Dr Platt, James Gourzis, Dale Conaway, and Henry Esber, each of whom resigned from the company’s board of directors. Dr Platt and Eliezer Zomer, who resigned, will provide advisory and consulting services to Pro-Pharmaceuticals during a two-year transition period.
Dr Zucconi said: “We would like to thank Dr Platt for his leadership and tireless work to get Pro from an idea to what has become a clear path toward FDA approval and commercialization of Davanat.”